Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular

A Khwaja1, P Rodriguez-Viciana, S Wennström

  • 1Imperial Cancer Research Fund, London, UK.

The EMBO Journal
|May 15, 1997
PubMed

Insights

Ras oncogenes prevent anoikis, a form of apoptosis, by activating phosphoinositide 3-OH kinase (PI 3-kinase) and protein kinase B/Akt (PKB/Akt). This pathway mediates survival signals in both normal and Ras-transformed epithelial cells.

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Cancer Research

Background:

  • Epithelial cells undergo anoikis (apoptosis) upon detachment from the extracellular matrix.
  • Oncogenic Ras proteins can inhibit anoikis, promoting cancer cell survival.
  • The specific signaling pathways involved in anoikis inhibition by Ras are not fully understood.

Purpose of the Study:

  • To elucidate the signaling mechanisms by which oncogenic Ras and extracellular matrix attachment prevent anoikis.
  • To identify the key molecular mediators of anoikis resistance in epithelial cells.

Main Methods:

  • Investigated the role of phosphoinositide 3-OH kinase (PI 3-kinase) and Raf signaling pathways.
  • Utilized constitutively active and inhibitory forms of PI 3-kinase and protein kinase B/Akt (PKB/Akt).
  • Assessed apoptosis in adherent and detached epithelial cells, including Ras-transformed cells.

Main Results:

  • PI 3-kinase, acting through PKB/Akt, mediates survival against anoikis induced by matrix detachment.
  • Constitutive activation of PI 3-kinase or PKB/Akt prevents anoikis.
  • Inhibition of PI 3-kinase blocks Ras-mediated anoikis protection, while PKB/Akt inhibition does not.
  • PI 3-kinase and PKB/Akt activity are elevated in Ras-transformed cells, even in suspension.

Conclusions:

  • PI 3-kinase and PKB/Akt are key mediators of anoikis resistance in Ras-transformed cells.
  • This pathway is also crucial for matrix-induced survival of normal epithelial cells.
  • Targeting PI 3-kinase/PKB/Akt may offer therapeutic strategies for cancers exhibiting anoikis resistance.

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...